POINT Biopharma Global Management
Management criteria checks 4/4
POINT Biopharma Global's CEO is Joe McCann, appointed in Jan 2020, has a tenure of 3.92 years. total yearly compensation is $2.84M, comprised of 16.9% salary and 83.1% bonuses, including company stock and options. directly owns 3.28% of the company’s shares, worth $43.70M. The average tenure of the management team and the board of directors is 2.5 years and 3 years respectively.
Key information
Joe McCann
Chief executive officer
US$2.8m
Total compensation
| CEO salary percentage | 16.9% |
| CEO tenure | 3.9yrs |
| CEO ownership | 3.3% |
| Management average tenure | 2.5yrs |
| Board average tenure | 3yrs |
Recent management updates
Recent updates
POINT Biopharma Global Inc. (NASDAQ:PNT) Analysts Just Slashed This Year's Estimates
Aug 20
We Think POINT Biopharma Global (NASDAQ:PNT) Can Easily Afford To Drive Business Growth
Feb 01A Look At The Fair Value Of POINT Biopharma Global Inc. (NASDAQ:PNT)
Oct 18Point Biopharma plummets on announcing common stock offering
Sep 13POINT Biopharma Global GAAP EPS of -$0.27 misses by $0.05
Aug 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | US$97m |
| Jun 30 2023 | n/a | n/a | US$97m |
| Mar 31 2023 | n/a | n/a | US$98m |
| Dec 31 2022 | US$3m | US$480k | US$98m |
| Sep 30 2022 | n/a | n/a | -US$79m |
| Jun 30 2022 | n/a | n/a | -US$72m |
| Mar 31 2022 | n/a | n/a | -US$56m |
| Dec 31 2021 | US$740k | US$392k | -US$46m |
| Sep 30 2021 | n/a | n/a | -US$37m |
| Jun 30 2021 | n/a | n/a | -US$23m |
| Mar 31 2021 | n/a | n/a | -US$18m |
| Dec 31 2020 | US$282k | US$218k | -US$13m |
Compensation vs Market: Joe's total compensation ($USD2.84M) is below average for companies of similar size in the US market ($USD5.06M).
Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.
CEO
Joe McCann (45 yo)
3.9yrs
Tenure
US$2,839,772
Compensation
Dr. Joe McCann, Ph.D. is Chief Executive Officer at POINT Biopharma Global Inc. since January 2020 and has been its Director since September 2019. Dr. McCann has overall responsibility for the day-to-day o...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 4.3yrs | US$2.57m | 8.19% $ 109.1m | |
| CEO & Director | 3.9yrs | US$2.84m | 3.28% $ 43.7m | |
| Chief Medical Officer & Director | 3.9yrs | US$598.69k | 2.82% $ 37.6m | |
| Executive Vice President of Clinical Development | 3.3yrs | US$1.87m | 0% $ 0 | |
| CFO & Corporate Secretary | 3.3yrs | US$703.01k | no data | |
| Chief Operating Officer | 2yrs | no data | no data | |
| SVP of People & Culture | less than a year | no data | no data | |
| VP of Corporate Affairs & Chief of Staff | no data | no data | no data | |
| Executive Vice President of Regulatory Affairs | 2.5yrs | no data | no data | |
| Senior Vice President of Business Development | 1.9yrs | no data | no data | |
| Executive VP of Commercial | 1.5yrs | no data | no data | |
| Senior Vice President of Chemistry Manufacturing & Controls | less than a year | no data | no data |
2.5yrs
Average Tenure
52yo
Average Age
Experienced Management: PNT's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 4.3yrs | US$2.57m | 8.19% $ 109.1m | |
| CEO & Director | 4.3yrs | US$2.84m | 3.28% $ 43.7m | |
| Chief Medical Officer & Director | 4.3yrs | US$598.69k | 2.82% $ 37.6m | |
| Independent Director | 3.6yrs | US$176.85k | 0.037% $ 487.6k | |
| Independent Director | 2.5yrs | US$170.00k | 0.0016% $ 21.3k | |
| Independent Director | 3yrs | US$184.35k | 0.020% $ 269.9k | |
| Lead Independent Director | 3yrs | US$210.24k | 0.039% $ 523.4k | |
| Independent Director | 2.5yrs | US$170.00k | 0.0035% $ 46.2k | |
| Director | less than a year | no data | no data |
3.0yrs
Average Tenure
59yo
Average Age
Experienced Board: PNT's board of directors are considered experienced (3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/12/28 21:08 |
| End of Day Share Price | 2023/12/26 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
POINT Biopharma Global Inc. is covered by 11 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhiqiang Shu | Berenberg |
| Brian Kemp Dolliver | Brookline Capital Markets |
| Charles Zhu | Guggenheim Securities, LLC |